Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00081796 | Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer | PHASE3 | COMPLETED | 438 | — | — | Apr 1, 2004 | Sep 1, 2006 | Aug 21, 2008 | 187 | United States, Argentina +24 |
| NCT00327743 | Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer | PHASE1 | COMPLETED | 34 | — | — | Aug 1, 2006 | Mar 1, 2009 | May 18, 2016 | 2 | United States, France |
| Arm | Type | Description |
|---|---|---|
| larotaxel + Capecitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| larotaxel (RPR109881, XRP9881) | DRUG | - |
| capecitabine | DRUG | - |
| larotaxel | DRUG | IV infusion on Day 1 of a 21-day cycle |
Eligibility Criteria In order to be eligible for this trial you must: * Have a diagnosis of breast cancer that is now metastatic (meaning the cancer has spread beyond its original location) or a recurrence of the cancer in its original location that cannot be removed by surgery. * Have received pr...